Author

N. W. Cho

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1

Frequent Co-Authors

K. J. Hiam-Galvez· 3 shared M. H. Spitzer· 3 shared J. L. Yee· 2 shared R. DeBarge· 2 shared A. Choudhury· 1 shared A. Perry· 1 shared B. V. Lien· 1 shared B. Y. Nabet· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

K. J. Hiam-Galvez

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Epigenetic reprogramming shapes the cellular landscape of schwannoma

S. J. Liu, T. Casey-Clyde, N. W. Cho, J. Swinderman, M. Pekmezci, M. C. Dougherty, K. Foster, W. C. Chen, J. E. Villanueva-Meyer, D. L. Swaney, H. N. Vasudevan, A. Choudhury, J. D. Breshears, U. E. Lang, C. D. Eaton, , D. R. Raleigh

This study identifies two molecular groups in schwannomas driven by epigenetic reprogramming and shows ionizing radiation can reprogram neural crest to immune-enriched schwannomas.

Nature Communications · Jan 12, 2024Peer-reviewedCancer Biology

T cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL-1 and TNFa Inflammation.

N. W. Cho, S. M. Guldberg, B. Y. Nabet, J. Z. Yu, E. J. Kim, K. J. Hiam-Galvez, J. L. Yee, R. DeBarge, I. Tenvooren, N. A. Ashitey, F. Lynce, D. A. Dillon, J. M. Rosenbluth, M. H. Spitzer

The paper identifies a novel mechanism of ICI resistance where T cells drive inflammatory resistance via IL-1 and TNF in tumors, with implications for therapy.

bioRxiv · Sep 20, 2022Immunology

Transient dendritic cell activation diversifies the T cell response to acute infection

K. J. Hiam-Galvez, R. Debarge, C. A. Lareau, N. W. Cho, J. L. Yee, T. L. H. Okholm, M. H. Spitzer

The paper shows that transient dendritic cell activation during acute infection shapes T cell fate by timing their priming and influencing whether they become effector or memory cells.

bioRxiv · Sep 26, 2021 · PreprintImmunology